Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™

Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™

老虎证券老虎证券2026/04/21 13:06
Show original
The partner led a financing round totaling $5.5 million, aimed at completing the acquisition of Celularity Inc.'s degenerative disease treatment business unit. This strategic financing will significantly accelerate Nexgel's business expansion in the field of cell therapy by integrating Celularity's patented technology platform and clinical assets in degenerative diseases, strengthening its competitiveness in the regenerative medicine market. Sequence Lifescience™, as an innovative platform focused on life sciences investment, spearheaded this financing, demonstrating market recognition of Nexgel's technological approach and commercial prospects. Upon completion of the transaction, Nexgel will gain access to Celularity's R&D pipeline and related intellectual property rights in fields such as neurodegenerative and osteoarticular diseases, further enriching its product portfolio. This acquisition aligns with the company's long-term plans for strategic transformation into high-growth therapeutic areas and is expected to generate significant synergies.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11

SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.

The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).

智通财经2026/09/22 07:11